use of cryptocurrencies, Featured

Japan Life Insurance announced that it would spend $8.2 billion to acquire the life insurance company Resolution Life. On December 11th, Japan Life Insurance Mutual announced that it would spend about $8.2 billion to acquire the remaining 77% shares of the life insurance company Resolution Life. The transaction is expected to be completed in the second half of 2025. On the same day, Japan Life announced that it would acquire the remaining 20% shares of MLC Life Insurance from National Bank of Australia (NAB) and integrate MLC with Resolution Life.Listed companies are enthusiastic about dividends. The Standard & Poor's dividend ETF(562060) rose by 0.53% at midday, and the constituent stocks were all red. By midday on December 11th, the standard & poor's dividend ETF(562060) rose by 0.53%, with a turnover of 28,056,300 yuan. The constituent stocks were all red, Lu 'an Huaneng rose by 2.13%, Orchid Kechuang and Voice Holdings rose by nearly 2%, and Aopu Technology and Pingmei shares followed suit. In the news, Wind data shows that as of December 10th, 267 listed companies have issued dividend plans for the third quarter, and 696 listed companies have issued dividend plans for the semi-annual period. The number of dividend plans for the third quarter and semi-annual period has reached record highs. According to industry insiders, dividends of listed companies will bring certain returns to investors, enhance investors' confidence, help attract long-term funds and enhance the stability and activity of the market. To sum up, in the period of high-quality economic growth, companies with higher dividend-paying ability and willingness are expected to be more and more favored by funds, and investors can try their best to seize the long-term opportunity of dividend theme by using the standard general dividend ETF(562060).Hong Kong stocks fell, while the Hang Seng Index and Hang Seng Technology Index both fell.

Beijing Stock Option Pioneer Venture Capital Fund was registered and established with a capital contribution of 100 million yuan. According to Tianyancha App, recently, the Stock Option Pioneer Venture Capital Fund (Limited Partnership) was established. The executive partner is Beijing Zhongguancun Capital Fund Management Co., Ltd., with a capital contribution of 100 million yuan. Its business scope is venture capital, and private equity funds are engaged in equity investment, investment management, asset management and other activities. According to the partner information, the fund is jointly funded by Beiyin Wealth Management Co., Ltd., Beijing Zhongguancun Capital Fund Management Co., Ltd. and Beijing Harmony Jiarui Investment Management Co., Ltd.Well-known American experts said that it was useless for Taiwan Province to buy weapons, and the Taiwan Affairs Office responded. Beijing Daily reporter: Bu Ruizhe, former chairman of the Board of Directors of the American Association in, and many other well-known American experts on the Taiwan Strait said that it was "impossible and useless" for the Democratic Progressive Party authorities to plan to increase military spending and buy American armaments in large quantities, which was regarded as "throwing cold water on the Democratic Progressive Party authorities" and "taking a blow". What is the spokesman's comment on this? Zhu Fenglian, spokesperson of the Democratic Progressive Party Affairs Office, said: authorities are trying to "seek independence by force", squandering the hard-earned money of Taiwan Province people to buy weapons, and paying a high "protection fee" to hand in a "warlords", which is just to quench their thirst by drinking poison, and will only make Taiwan Province soldiers in danger. The deeper the "relying on foreign countries for independence", the more "destroying Taiwan", and ultimately it will only be a moth to the fire and bring about its own destruction.I SQUARED CAPITAL is reported to have started due diligence on Hong Kong Broadband.

Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.Xinshida Inverter has successfully obtained the type approval certificate of China Classification Society. Recently, Xinshida Inverter AS710M has successfully obtained the type approval certificate issued by China Classification Society (CCS), which indicates that Xinshida Electric's products meet the strict standards of the international shipping industry, and also indicates that the company will further expand its market share in the field of ship and ocean engineering.Yongtai Bio-product, a new open-source shareholding company, was recognized by CDE for breakthrough therapy. On December 11th, official website, China National Medical Products Administration Drug Evaluation Center (CDE), recently announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (CAR-T-19 cell injection for short) developed by Yongtai Bio-B (06978.HK) was successfully included in the list of breakthrough therapy varieties by CDE, and the indication was recurrence under 25 years old/.